Research Group in Medical Chemistry for Drug Development

Metabolism and Organic Damage Area

Peroxisome proliferator activator receptors (PPARs)

Liver X receptors (LXR)

Dopamine receptors

Biomarkers of inflammation

Dra. Nuria Cabedo Escrig
Dra. Nuria Cabedo Escrig

Leading, R4
Established, R3

Nuria Cabedo Escrig    

Recognised/Emerging, R2
First Stage, R1

Ainhoa García Martín
Alvaro Bernabeu Sanchís

Collaborating Researchers

Diego Cortés Martínez
Jordi Ferri Císcar


Laura Vila Dasí

Administrative assistant
Benzopyran hydrazones with dual PPARalpha/gamma or PPARalpha/delta agonism and an anti-inflammatory effect on human THP-1 macrophages. Garcia A, Vila L, Duplan I, Schiel M, Enriz R, Hennuyer N, Staels B, Cabedo N, Cortes D. European Journal of Medicinal Chemistry. 2024 Feb 5:265:116125. doi: 10.1016/j.ejmech.2024.116125. PMID: 38185055

Anti-inflammatory effects and improved metabolic derangements in ob/ob mice by a newly synthesized prenylated benzopyran with pan-PPAR activity. Marques P, Villarroel-Vicente C, Collado A, Garcia A, Vila L, Duplan I, Hennuyer N, Garibotto F, Enriz RD, Dacquet C, Staels B, Piqueras L, Cortes D, Sanz MJ, Cabedo N. Pharmacological Research. 2023 Jan;187:106638. doi: 10.1016/j.phrs.2022.106638. PMID: 36586645

Remission of graves disease after initiation of ocrelizumab in patients with multiple sclerosis. Casany-Fernandez R, Gascon-Gimenez F, Matarredona Solaz E, Pardo Lozano F, Dominguez-Moran J, Ferri Ciscar J, Real J. Thyroid. 2023 Feb;33(2):267-269. doi: 10.1089/thy.2022.0398. PMID: 36416241

Synthesis of 2-aminopropyl benzopyran derivatives as potential agents against triple-negative breast cancer. García A, Torres-Ruiz S, Vila L, Villarroel-Vicente C, Bernabeu A, Eroles P, Cabedo N, Cortes D. RSC Medicinal Chemistry. 2023 Oct 4;14(11):2327-2341. doi: 10.1039/d3md00385j. PMID: 38020071

Corticotroph cell hyperplasia as a rare cause of ACTH-dependent Cushing syndrome. Ferri J, Martinez-Ibanez J, Terradez L, Savall E, Martinez-Hervas S, Oller M, Lorente R, Ascaso J, Real J. Endocrinologia, Diabetes y Nutrición. 2022 Nov;69(9):694-701. doi: 10.1016/j.endien.2022.11.004. PMID: 36470644

Effect of personality on blood glucose control in patients with type 1 diabetes. Gu Hong W, Ferri J, Ampudia-Blasco F, Martin-Brufau R, Peiro M, Benito E, Martinez-Hervas S, Sanz M, Real J. Endocrinologia, Diabetes y Nutricion. 2022 Nov;69(9):677-685. doi: 10.1016/j.endien.2021.11.034. PMID: 36470643

Synthesis and biological studies of polycerasoidol and trans-delta-tocotrienolic acid derivatives as PPARalpha and/or PPARgamma agonists. Vila L, Cabedo N, Villarroel-Vicente C, Garcia A, Bernabeu A, Hennuyer N, Staels B, Franck X, Figadere B, Sanz MJ, Cortes D. Bioorganic & Medicinal Chemistry. 2022 Jan 1;53:116532. doi: 10.1016/j.bmc.2021.116532. PMID: 34863066

Natural products and analogs as preventive agents for metabolic syndrome via peroxisome proliferator-activated receptors: an overview. Villarroel-Vicente C, Gutierrez-Palomo S, Ferri J, Cortes D, Cabedo N. European Journal of Medicinal Chemistry. 2021 Oct 5;221:113535. doi: 10.1016/j.ejmech.2021.113535. PMID: 33992930

Synthesis of 2-prenylated alkoxylated benzopyrans by horner- wadsworth-emmons olefination with PPAR alpha/gamma agonist activity. Garcia A, Vila L, Marin P, Bernabeu A, Villarroel-Vicente C, Hennuyer N, Staels B, Franck X, Figadere B, Cabedo N, Cortes D. ACS Medicinal Chemistry Letters. 2021 Oct 6;12(11):1783-1786. doi: 10.1021/acsmedchemlett.1c00400. PMID: 34795868

Reference: PI21/02045
Title: Desarrollo de nuevos moduladores multidiana de receptores nucleares y biomarcadores lipídicos para el tratamiento del síndrome metabólico y las comorbilidades asociadas
Funding body: Instituto de Salud Carlos III – Cofinanciado FEDER
Principal Investigator: Nuria Cabedo Escrig
Duration: 2022 – 2024
Total budget: 174.240 €
Reference: PI18/01450
Title: Desarrollo químico y farmacológico de nuevos fármacos “multidiana” en el tratamiento de la diabetes mellitus tipo 2 y la enfermedad cardiovascular asociada
Funding body: Instituto de Salud Carlos III – Cofinanciado FEDER
Principal Investigator: Nuria Cabedo Escrig
Duration: 2019 – 2022
Total budget: 61.710 €
Reference: COST Action CA15135
Title: Multi-target paradigm for innovative ligand identification in the drug discovery process (MuTaLig)
Funding body: European Commission
Principal Investigator: Stefano Alcaro
Duration: 2016 – 2020
Total budget:
Reference: CP15/00150
Title: Synthesis and pharmacological evaluation of new dual PPARalpha/gamma agonists as new therapeutic tools in the control of cardiometabolic disorders
Funding body: Instituto de Salud Carlos III – Cofinanciado FEDER
Principal Investigator: Nuria Cabedo Escrig
Duration: 2016 – 2021
Total budget: 121.500 €